Literature DB >> 11933919

Endomyocardial biopsy findings in 50 patients with idiopathic atrioventricular block: presence of myocarditis.

A Uemura1, S Morimoto, S Hiramitsu, H Hishida.   

Abstract

In patients with primary atrioventricular (AV) conduction disturbances, lesions are commonly believed to be limited to the conduction system. In the present study, myocardial lesions were analyzed histologically in patients with AV conduction disturbances to determine the presence of myocarditis. We studied 50 patients with second or third degree AV block in whom the cause was not clear (AVB group). Endomyocardial biopsy was performed from the right ventricle and examined by light microscopy. Tissue specimens also were obtained from 12 normal hearts at autopsy as a control group (N group). The diagnosis of myocarditis was based on the Dallas criteria. The myocyte transverse diameter was 15.4+/-4.1 microm in the AVB group and 11.7+/-3.1 microm in the N group (P<0.01). The fibrosis area ratio also was significantly higher in the AVB group than in the N group (10.1+/-6.7% vs 5.1+/-2.0%). The mean number of lymphocytes per 400-fold magnified field was significantly greater in the AVB group than in the N group (1.9+/-1.6 vs 1.3+/-0.4). In addition, disorganization of the cardiac myocytes was noted in 8 patients in the AVB group (16%), myocyte disarrangement in 39 patients (78%), myocytolysis in 23 patients (46%), and nuclear deformity in 21 patients (42%). Myocarditis was diagnosed in 3 of the 50 patients (6%). The present study demonstrates that myocardial lesions can be detected in a large proportion of patients with AV conduction disturbances. Furthermore, myocarditis is present in 6% of the cases.

Entities:  

Mesh:

Year:  2001        PMID: 11933919     DOI: 10.1536/jhj.42.691

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  10 in total

1.  When should high-grade heart block trigger a search for a treatable cardiomyopathy?

Authors:  Leslie T Cooper; Lori A Blauwet
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-06

Review 2.  Myocarditis.

Authors:  Sandeep Sagar; Peter P Liu; Leslie T Cooper
Journal:  Lancet       Date:  2011-12-18       Impact factor: 79.321

Review 3.  Immune cell diversity contributes to the pathogenesis of myocarditis.

Authors:  Xiumeng Hua; Jiangping Song
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 4.  Corticosteroids for viral myocarditis.

Authors:  Huai Sheng Chen; Wei Wang; Sheng Nan Wu; Jian Ping Liu
Journal:  Cochrane Database Syst Rev       Date:  2013-10-18

5.  Myocarditis in dogs: etiology, clinical and histopathological features (11 cases: 2007-2013).

Authors:  Izabela Janus; Agnieszka Noszczyk-Nowak; Marcin Nowak; Alicja Cepiel; Rafał Ciaputa; Urszula Pasławska; Piotr Dzięgiel; Karolina Jabłońska
Journal:  Ir Vet J       Date:  2014-12-24       Impact factor: 2.146

6.  Third-Degree Atrioventricular Block and Collapse Associated with Eosinophilic Myocarditis in a Horse.

Authors:  D Luethy; J Slack; M S Kraus; A R Gelzer; P Habecker; A L Johnson
Journal:  J Vet Intern Med       Date:  2017-03-14       Impact factor: 3.333

7.  COVID-19 BBIBP-CorV vaccine and transient heart block - A phenomenon by chance or a possible correlation - A case report.

Authors:  Pirbhat Shams; Jamshed Ali; Sheema Saadia; Aamir Hameed Khan; Fateh Ali Tipoo Sultan; Javed Tai
Journal:  Ann Med Surg (Lond)       Date:  2021-10-15

8.  Complete atrioventricular block in an adolescent with rheumatic Fever.

Authors:  Gyeong-Hee Yoo
Journal:  Korean Circ J       Date:  2009-03-25       Impact factor: 3.243

9.  Long-term Intrinsic Rhythm Evaluation in Dogs with Atrioventricular Block.

Authors:  R A Santilli; D M Porteiro Vázquez; T Vezzosi; M Perego
Journal:  J Vet Intern Med       Date:  2015-11-17       Impact factor: 3.333

Review 10.  Indications for permanent pacing in dogs and cats.

Authors:  R A Santilli; F Giacomazzi; D M Porteiro Vázquez; M Perego
Journal:  J Vet Cardiol       Date:  2019-01-29       Impact factor: 1.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.